cancer
The findings show that bacterial metabolites can sensitize cancer cells to treatment with immunotherapy by boosting the expression of HLA class I molecules.
Understanding how antibiotics influence the microbiota’s impacts on immunotherapy may inform strategies to identify cancer patients that are more likely to respond to cancer treatment.
MaaT033 (capsule), which is being developed as an adjunctive and maintenance therapy to improve overall survival in allo-HSCT, has received orphan drug designation (ODD) status from the European Medicines Agency…
The findings of a recent study suggest that FMT is an effective strategy to mitigate the intestinal side effects of cancer immunotherapy.
Pedro Correa de Sampaio, Chief Executive Officer at Neobe Therapeutics, talks about the challenges to remove immunosuppressive constraints that prevent the infiltration of immune cells in a subset of cancers.
The findings of a recent study suggest that targeting the interactions between MAdCAM-1 and specific receptors on the surface of immune cells may help to improve immunotherapy outcomes.
Nathalie Corvaïa, Chief Scientific Officer at MaaT Pharma, gives an overview of preclinical and clinical results for MaaT013 and MaaT033.
This partnership aims to leverage Microba's advanced technology platform for measuring the human gut microbiome to discover novel biomarkers for pancreatic cancer detection.
The findings of a recent study identified microbiota signatures that may allow clinicians to predict the outcomes of CAR-T immunotherapy.
Microbiomepost discussed with Lorella Tripodi, University Federico II of Naples, about the research she is working with her colleagues.
